Thursday, June 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

CRADA Opportunity: Developing Protein Nanoparticles for the Display of Viral Epitopes

by Global Biodefense Staff
March 13, 2019
Nanoscale CBRN Defense

Credit: Shutterstock

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health seeks to partner with one or more biomedical companies in developing protein nanoparticles for the display of viral epitopes for vaccine use.

The Cooperative Research and Development Agreement (CRADA) would require the following capabilities:

  • Produce scaled- up purified recombinant protein nanoparticles
  • Measure antibody levels/titers elicited by nanoparticles
  • Measure neutralization capacity of antibodies to a panel of influenza viruses
  • Produce hydridomas or cDNA clones of neutralizing antibody genes elicited by nanoparticles
  • Produce quantities of antibodies sufficient for challenge and protection studies in animal models

CRADA partners will be expected to carry out additional immunogenicity studies in small animal mouse models with NIAID’s protein nanoparticles and if the data are promising, clinical studies may be discussed. It is especially desired that a prospective CRADA partner has expertise in performing and analyzing vaccination of animals with influenza immunogens/viruses and has the ability to perform challenge and protection studies in animals with a candidate influenza vaccine to expand on the initial studies performed by NIAID.

Additional details are available via FedBizOpps Solicitation Number: NIAID-TTIPO-2016-032.

Tags: InfluenzaNIAIDRFIVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC